

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.

NAME Antonio C. Wolff	POSITION TITLE Associate Professor of Oncology		
eRA COMMONS USER NAME Awolff3			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Universidade Federal do Rio de Janeiro, Brazil	M.D.	1986	Medicine
American Board of Internal Medicine (Recertified)	Board Certified	1991-2011	Internal Medicine
American Board of Internal Medicine (Recertified)	Board Certified	1995-2014	Medical Oncology

A. Personal Statement

I am a breast cancer clinical trialist with expertise in clinical trials, predictive biomarkers, and clinical practice guidelines. I am a member of the breast core committee of the Eastern Cooperative Oncology Group and co-chair its Developmental Therapeutics Working Group. I am also co-chair of the Cancer Review Committee of the Johns Hopkins Kimmel Cancer Center. I was leader of the breast cancer education track for the 2010 ASCO annual meeting, and serve as co-chair the ASCO/College of American Pathologists Panels that developed clinical practice guidelines on HER2 and hormone receptor testing in breast cancer. In 2010, I received an NCI Cancer Clinical Investigator Team Leadership Award to recognize my activities as a breast cancer clinical researcher. I am also a member of ASCO's Quality of Care Committee and past chair of ASCO's Health Services Research Committee, now known as the Clinical Practice Guidelines Committee and that oversees all ASCO's efforts in the development, dissemination, and implementation of practice guidelines. I have a record of successful and productive collaborative research in breast cancer, clinical trials, integration of research findings into clinical practice, and quality initiatives, and serve as Executive Officer of the Translational Breast Cancer Research Consortium. Therefore, I have the necessary methodological and content expertise to serve as a co-investigator with Drs. Peter van Zijl and Dmitri Artemov in Research Component 3, and with Drs. Glunde and Li in Research Component 4.

B. Positions and Honors

Positions and Employment

1987-88	Residency Internal Medicine, Universidade Federal do Rio de Janeiro, Brazil
1988-90	Residency Internal Medicine, Good Samaritan Hospital of Maryland, Baltimore, MD
1990-91	Residency Internal Medicine, Mount Sinai Medical Center, New York, NY
1991-92	Fellowship Hematology/Oncology, Washington University Medical Center, St. Louis, MO
1992-95	Fellowship Medical Oncology, The Johns Hopkins Oncology Center, Baltimore, MD
1995-98	Assistant Professor of Medicine, Emory University School of Medicine, Atlanta, GA
1998-05	Assistant Professor of Oncology, Johns Hopkins Kimmel Cancer Center, Baltimore, MD
2005	Associate Professor of Oncology, Johns Hopkins Kimmel Cancer Center, Baltimore, MD

Other Experience, Honors, and Professional Memberships

1991-present	Member, American College of Physicians
1993-95	Associate Member, American Association for Cancer Research
1995-present	Active Member, American Association for Cancer Research
1995-present	Member, Eastern Cooperative Oncology Group (ECOG)
1996-present	Active Member, American Society of Clinical Oncology (ASCO)
1997-98	Chief, Hematology and Oncology Section, Atlanta V.A.M.C.
1999-present	Member, ECOG Breast Cancer Core Committee
1999-06	Co-Director, Medical Oncology Fellowship Program
2002-present	Associate Member, European Society of Medical Oncology (ESMO)
2002-04	Member, ASCO Scientific Program Committee
2002-08	Member, ASCO Health Services Committee
2004-present	Fellow, American College of Physicians
2006-07	Chair, ASCO Health Services Committee

2007-10	Member, ASCO Quality Care Committee
2007-09	Member, ASCO Education Committee (2010 Annual Meeting Breast Track Leader)
2009-11	NCI Cancer Clinical Investigator Team Leadership Award
2010	ASCO Statesman Award

C. Selected Peer-reviewed Publications (partial list of 15 publications)

Most relevant to the current application

1. Marchionni L, Wilson RF, Wolff AC, Marinopoulos S, Parmigiani G, Bass EB, and Goodman SN. Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer. *Annals Int Med*, 2008; 148(5):358-69. PMC Journal - In Process.
2. Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, and Zujewski J. Special Series (Breast Cancer): Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer. *J Clin Oncol*, 2008; 26(5): 806-13, PMC Journal - In Process.
3. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge Jr GW, Wood WC, Davidson NE, Weekly paclitaxel improves survival in lymph node positive and high risk node negative operable breast cancer. *N Engl J Med*, 2008; 358(16):1663-71. PMID:2743943.
4. Zellars R, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange JR, Jacobs LK, Emens L, Armstrong DK, Fetting JH, Garrett-Mayer E, Davidson NE, and Wolff AC. Partial Breast Irradiation and Concurrent dose-dense Doxorubicin and Cyclophosphamide. *J Clin Oncol* 2009; 27(17):2816-22, PMC Journal - In Process.
5. Muss H, Berry D, Cirincione C, Theodoulou M, Mauer A, Kornblith A, Partridge A, Dressler L, Cohen H, Becker H, Norton L, Kartcheske P, Wheeler J, Perez E, Wolff AC, Gralow J, Burstein H, Mahmood A, Parker B, Hudis C, Winer EP, for the Cancer and Leukemia Group B. Adjuvant Chemotherapy with Standard Regimens is Superior to Capecitabine in Older Women with Early Stage Breast Cancer. *N Eng J Med*, 2009; 360(20):2055. PMC Journal - In Process.
6. Wolff AC, Wang M, Li H, Pins MR, Pretorius FJ, Rowland KM, Sparano JA, Davidson NE. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. *Breast Cancer Res Treat*. 2010 May;121(1):111-20. Epub 2010 Mar 24. PMC Journal - In Process.

Additional recent publications of importance to the field (in chronological order)

1. Wolff AC, Hammond MEH, Schwartz JN, Hagerty K, Allred DC, Cote R, Dowsett M, Fitzgibbons PL, Gutman S, Hanna W, Keegan P, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube S, Tubbs R, Vance GH, van de Vijver M, Wheeler T, Yost J, Hayes DF. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for HER2 Testing in Breast Cancer, *J Clin Oncol*, 2007; 25: 118-145.
2. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. A phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol*. 2008; 26:1810-6. PMC Journal - In Process.
3. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. *J Clin Oncol*. 2009;27:5911-8 PMID: [PMC2793039](#) [Available on 2010/12/10].
4. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. Pharmacogenetic Pathway Analysis of Docetaxel Elimination. *Clin Pharmacol Ther*. 2009;85:155-63. PMC Journal - In Process.
5. Chumsri S, Jeter S, Jacobs LK, Nassar H, Armstrong DK, Emens LA, Fetting JH, Lange JR, Riley C, Tsangaris TN, Wolff AC, Zellars R, Zhang Z, Stearns V. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. *Clin Breast Cancer*. 2010;10:40-5 PMC Journal - In Process.
6. Jacobs MA, Stearns V, Wolff AC, Macura K, Khouri N, Tsangaris TN, Davidson NE, Bhujwala Z, Bluemke DA, Ouwkerk R. Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. *Acad Radiology*, 2010, [Epub ahead of print] PMC Journal - In Process.

7. Hammond EH, Hayes DF, Dowsett M, Allred DC, Hagerty K, Badve S, Fitzgibbons PL, Francis G, Goldstein N, Hayes M, Hicks D, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep F, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, and Wolff AC. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen/Progesterone Receptors in Breast Cancer. J Clin Oncol. 2010 Apr 19. [Epub ahead of print] PMID: PMC2881855 [Available on 2011/6/1].
8. Chavez-MacGregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, BondyML, and Gonzalez-Angulo AM. Pathological complete response in breast cancer patients receiving anthracycline and taxane-base neoadjuvant chemotherapy: Evaluating the effect of race/ethnicity. Cancer 2010 PMC Journal - In Process.
9. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb MJ, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, and Wolff AC. Breast cancer. Clinical practice guidelines in oncology J Natl Compr Canc Netw 2009 7(2): p. 122 PMC Journal - In Process.

D. Research Support

Ongoing Research Support

NIH1R01CA149616-01A1 (Frick/Snyder) 07/01/10-06/30/13

Comorbid Conditions in Cancer Survivors: Costs and Quality of Care

The purpose of this study is to use the SER-Medicare dataset to compare the quality of care for comorbid conditions requiring acute interventions between cancer survivors and non-cancer controls, the rates of avoidable outcomes, and the association between quality indicators and costs.

2P50CA103175 (Bhujwalla) 09/22/11- 07/31/16

NIH - JHU ICMIC Program

The JHU ICMIC Program consists of four research components, four developmental projects, four resources, and a career development component. The four research components have a major emphasis on clinical translation and cover different aspects of understanding, detecting, and treating cancer. The major goal of this research component of the JHU ICMIC is to develop CEST MR pulse sequence technology for molecular MRI of breast cancer.

Bristol-Meyers Squibb, Co. (Wolff) 03/06/12 – 03/05/15

A Phase 2 Study of BMS-754807 Combined with Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects with Acquired Resistance to Non-Steroidal Aromatase Inhibitor

This study is testing an IGFR TKI to reverse endocrine resistance.

P50 CA88843 (Sukumar) 09/30/00 - 09/29/12

SPORE in Breast Cancer

Project 1: Molecular Markers in Breast Cancer

The overall goal of this proposal is to identify major molecular alterations in carcinoma of the breast by microarray analysis of all stages of tumor development, and develop markers for early detection.

KG110094 (Umbricht) 04/01/11 - 03/31/14

The Susan G. Komen for the Cure Foundation

Molecular Marker Signature Prognostic of Metastatic Disease in Node-negative ER-Negative Breast Cancer with no systemic therapy.

The major goals of this project are to identify molecular markers (RNA expression and methylation) that have differential prognostic utility in early stage breast cancer patients with ER-negative disease.

NCI U10 CA016116-31 (Forastiere) 05/01/10 - 04/30/16

Eastern Cooperative Oncology Group (ECOG)

The major goals of this project are to develop and implement clinical research protocols and correlative laboratory studies within ECOG.

90021105 (Wolff) 10/01/05 - 09/30/12

Breast Cancer Research Foundation-TBCRC

Translational Breast Cancer Research Consortium

To support a clinical trial network across sixteen cancer centers.

K90033529 (Wolff) 03/05/08 - 05/31/13
 Susan G. Komen for the Cure-TBCRC
 Proposal for a Partnership between the Translational Breast Cancer Research Consortium and the Susan G. Komen for the Cure Foundation.

90034357 (Wolff) 04/01/09 - 04/30/13
 Genentech
 GDC4627g A Phase Ib, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and activity of Trastuzamub-MCC-DM1 administered intravenously and GDC-0941 administered orally to patients with He.

NIH R01CA149616 (Frick) 07/01/10 - 06/30/13
 Comorbid Conditions in Cancer Survivors: Costs and Quality of Care
 The purpose of this study is to use the SER-Medicare dataset to compare the quality of care for Comorbid conditions requiring acute interventions between cancer survivors and non-cancer controls, the rates of avoidable outcomes, and the association between quality indicators and costs.

90038593 (Wolff) 06/01/09 - 12/31/12
 National Comprehensive Cancer Network
 Breast Cancer Outcomes Database
 The purpose of this grant is to fund prospective database efforts in early stage breast cancer.

Completed Projects Within Last Three Years

NIHR21 CA134805-01A1 (Snyder/Wu) 08/01/09-07/31/11
 Feasibility and Value of a Website for Assessing Patient Reported Outcomes
 The purpose of this study is to assess the use, usefulness, and acceptability of a website designed to collect patient-reported outcomes from cancer outpatients and link the data with the electronic medical record.

Susan G. Komen for the Cure Maryland (Wolff) 07/01/08-06/30/11
 A Survivorship Program for Breast Cancer: A Transition for Patients and Providers
 The major goal of this project is to establish breast cancer follow-up care strategies for survivors and their health care providers and a comprehensive clinical and educational services model adaptable for use elsewhere.

P50 CA88843 SPORE in Breast Cancer (Sukumar) 09/30/00-09/29/11
 Project 1: Molecular Markers of Breast Cancer
 Specialized Program in Research Excellence (SPORE in Breast Cancer)
 The overall goal of this proposal is to identify major molecular alterations in carcinoma of the breast by microarray analysis of all stages of tumor development, and develop markers for early detection.

The Susan G. Komen for the Cure Maryland (Wolff) 04/01/00-03/31/11
 Project CRAFT (annual competitive application)
 Enhancing Accrual of Women with Breast Cancer to NCI-Sponsored Clinical Trials at Johns Hopkins
 The major goal of this project is to increase the accrual of women with breast cancer to NCI-sponsored clinical trials at Johns Hopkins.

Breast Cancer Research Foundation /TBCRC (Wolff) 10/01/05-09/30/11
 Translational Breast Cancer Research Consortium
 To support a clinical trial network across 16 academic breast cancer centers and breast SPORE's.

Avon Foundation/TBCRC (Wolff) 07/01/06-06/30/11
 Translational Breast Cancer Research Consortium
 To support a clinical trial network across 16 academic breast cancer centers and breast SPOREs.

Susan G. Komen for the Cure/TBCRC (Wolff) 03/05/08-05/31/11
 To support a clinical trial network across 16 academic breast cancer centers and breast SPOREs.

NIH RO1CA100184 (Jacobs) 09/01/04-08/31/11
 Multiparametric MRI Characterization of Breast Tissue
 The major goal of this project is to develop an MRI multiparametric model for use in screening of high-risk patients and to predict response to therapy in patients receiving preoperative systemic therapy.

Avon Foundation 01-2008-012 (Nelson) 07/01/08-06/30/11
 2008 Avon Breast Center of Excellence

Serum DNA Methylation as a Tumor Marker

A renewed and enhanced partnership for the understanding, treatment, and cure of breast cancer.

This award supports six translational research projects, the Hopkins Avon Breast Center, clinical research infrastructure, and administration.

Genentech (Wolff)

04/01/08-03/31/10 NCE

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2 Positive Breast Cancer

The major goal of this trial is to assess the disease-free survival of breast cancer patients with HER2-positive disease treated with adjuvant paclitaxel and trastuzumab without an anthracycline.

NCI (Forastiere)

05/01/04-04/30/09

Eastern Cooperative Oncology Group (ECOG)

The major goals of this project are to develop and implement clinical research protocols and correlative laboratory studies within ECOG.

NIH1P50 CA 103175 (Bhujwala)

08/01/03-07/31/08

JHU ICMIC Program

This Center Grant is funded to establish an *In Vivo* Cellular and Molecular Imaging Center at Johns Hopkins.

The center grant consists of four RO1's, five developmental projects, five resources and a career developmental program.